---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Contraindications/Warnings/Precautions/Adverse effects"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Contraindications/Warnings/Precautions/Adverse effects. Covers Warnings and precautions. 16 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/contraindications-warnings-precautions-adverse-effects"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Contraindications/Warnings/Precautions/Adverse effects

<a id="heading-2.1.2.7"></a>

## 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

#### FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

#### Adverse events of special interest: Launch-HTN

> “Prespecified adverse events of special interest included dose reduction, interruption, or discontinuation due to hyperkalemia, hyponatremia, and reduction in kidney function (decline in eGFR) as well as treatment discontinuation due to glucocorticoid deficiency, symptomatic hypotension, severely elevated BP, or overdose of trial drug or prescribed antihypertensive medications.”
> “The prespecified adverse events of hyponatremia, hyperkalemia, and reduction in kidney function (decline in eGFR) were reported more with lorundrostat compared with placebo; however, few treatment discontinuations occurred due to these events.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

| Event, No. (%) | Lorundrostat 50 mg then 100 mg (n = 270) | Lorundrostat 50 mg (n = 538) | Placebo (n = 270) |
| --- | --- | --- | --- |
| Serious adverse event | “2 (0.7)” | “12 (2.2)” | “8 (3.0)” |
| Hypotension with symptoms | “5 (1.9)” | “11 (2.0)” | “1 (0.4)” |
| Hyperkalemia requiring modification of trial drug | “7 (2.6)” | “11 (2.0)” | “1 (0.4)” |
| Hyponatremia requiring modification of trial drug | “28 (10.4)” | “37 (6.9)” | “9 (3.3)” |
| Reduction in estimated glomerular filtration rate requiring modification of trial drug | “9 (3.3)” | “16 (3.0)” | “2 (0.7)” |
| Glucocorticoid deficiency confirmed by stimulation test | “0” | “0” | “3 (1.1)” |

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

<a id="topic-2.1.2.7.1-3"></a>

#### Hyperkalemia: Launch-HTN

> “A serum potassium level of greater than 6.0 mmol/L occurred in 4 participants (1.5%) randomized to 50 mg of lorundrostat group with possible dose escalation to 100 mg, in 6 participants (1.1%) randomized to 50 mg of lorundrostat, and in 2 participants (0.7%) randomized to placebo”
> “The mean serum potassium level increased in the 2 lorundrostat groups but remained within normal range”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 1.1% and 1.5% in the 50 mg and 50 to 100 mg arms, respectively.”
> “The per-protocol procedure for validation of suspected factitious hyperkalemia (most often due to phlebotomy-related hemolysis and release of potassium from red blood cells) specified a repeat potassium measurement within 72 hours while still taking study medication to confirm validity and provide an accurate determination of the true incidence of hyperkalemia.”
> “After exclusion of the spurious results, the incidence of confirmed hyperkalemia was 0.6% and 1.1% in the 50 mg and 50 to 100 mg arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-4"></a>

#### Hyperkalemia: Advance-HTN

> “A potassium level above 6.0 mmol per liter occurred in 5 participants (5%) in the stable-dose group, 7 participants (7%) in the dose-adjustment group, and no participants in the placebo group.”

Source: [Laffin et al. (2025b)](https://pubmed.ncbi.nlm.nih.gov/40267417/)

> “The incidence of hyperkalemia (serum potassium >6.0 mmol/L) at the scheduled study visit was 5.3% and 7.4% in the 50 mg and 50 to 100 mg arms, respectively.”
> “After exclusion of the spurious results, the incidence of confirmed hyperkalemia was 2.1% and 3.2% in the 50 mg and 50 to 100 mg arms, respectively.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-5"></a>

#### Hyperkalemia: Target-HTN

> “Mean serum potassium increases were similar across all lorundrostat doses, including increases of 0.25 mmol/L in the 50-mg and 100-mg once-daily groups. Six participants (3.6%) had serum potassium levels above 6.0 mmol/L during the trial”
> “No instances of hyperkalemia required intervention beyond discontinuation or reduction in the dose of lorundrostat.”
> “Lorundrostat has a relatively short half-life, and once-daily dosing resulted in a 25% lower mean change in serum potassium when 50 mg once daily was compared with 25 mg twice daily.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.7.1-6"></a>

#### Hyperkalemia: Explore-CKD

> “Hyperkalemia occurred more frequently with lorundrostat than with placebo (15.5% vs 3.5%), with 5.2% of lorundrostat-treated participants experiencing a confirmed serum potassium concentration >6.0 mmol/l.”
> “Per protocol modification of the study drug dose due to hyperkalemia and reduction in kidney function were the most common AEs of special interest, occurring in 8.6% (n = 5) and 10.3% (n = 6) of participants during lorundrostat treatment, respectively, versus none with placebo.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.7.1-7"></a>

#### Hyperkalemia: Explore-OSA

> “Lorundrostat demonstrated a favorable safety profile and was well tolerated, with no serum potassium excursions above 5.5 mmol/L.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-8"></a>

#### Hyperkalemia: company summary across trials

> “A majority of our clinical trial participants maintained a serum potassium in the normal range. There have been modest incidences of hyperkalemia requiring dose adjustment or discontinuation.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-9"></a>

#### Adverse events during 36 weeks of open-label treatment: Transform-HTN

| Event | Lorundrostat (N=632), n (%) |
| --- | --- |
| Any serious adverse event | “27 (4.3)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Hyperkalemia requiring modification of trial drug | “32 (5.1)” |
| Hyponatremia requiring modification of trial drug | “28 (4.4)” |
| Hypotension with symptoms | “13 (2.1)” |
| Serum potassium >6.0 mmol/L confirmed by repeat testing | “16 (2.5)” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

> “Consistent with lorundrostat’s mechanism of action, serum potassium increased and eGFR decreased early in treatment; both remained stable through the open-label period to Week 48.”

Source: [Mineralys Therapeutics press release, Transform-HTN results (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/129/mineralys-therapeutics-presents-new-late-breaking-data-from)

<a id="topic-2.1.2.7.1-10"></a>

#### Hyponatremia

> “Among participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, treatment discontinuation occurred in 1 (0.37%) due to hyperkalemia, in 1 (0.37%) due to hyponatremia, and in 0 due to reduction in kidney function (decline in eGFR). Among participants in the 50 mg of lorundrostat group, treatment discontinuation occurred in 2 (0.37%) due to hyperkalemia, in 2 (0.37%) due to hyponatremia, and in 3 (0.56%) due to reduction in kidney function (decline in eGFR).”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “A participant randomized to 100 mg once daily of lorundrostat in cohort 2 had worsening of hyponatremia necessitating stopping the drug.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “No serum sodium values <125 mmol/l occurred”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.7.1-11"></a>

#### Adverse events in Advance-HTN

| Event | Placebo | Lorundrostat 50 mg | Lorundrostat 50 to 100 mg |
| --- | --- | --- | --- |
| Any serious adverse event | “2%” | “6%” | “8%” |
| Hypotension | “3%” | “9%” | “8%” |
| Hyponatremia | “6%” | “9%” | “11%” |
| Hyperkalemia (>6.0 mmol/L), confirmed by repeat testing | “0” | “2%” | “3%” |

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

> “A dose escalation strategy from 50 to 100 mg did not lower blood pressure more than 50 mg and was associated with numerically more adverse events”

Source: [Laffin et al. (2025a)](https://mineralystx.com/wp-content/uploads/2025/03/ACC-2025_ADVANCE-HTN-LBCToral-25MARCH2025.pdf)

> “In the Advance-HTN trial, there were six participants (6.4%) and eight participants (8.4%) with treatment-emergent SAEs in the lorundrostat 50 mg and lorundrostat 50 to 100 mg arms, respectively, compared to two participants (2.1%) in the placebo arm.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-12"></a>

#### Decline in estimated glomerular filtration rate

> “Creatinine-based eGFR decreased by 9.3% from baseline to week 12 in the 2 lorundrostat groups and increased by 0.4% in the placebo group. Using the cystatin-C–based eGFR formula, eGFR decreased by 5.2% in the 50 mg of lorundrostat group with possible escalation to 100 mg, decreased by 4.1% in the 50 mg of lorundrostat group, and increased by 3.4% in the placebo group.”
> “An acute, reversible decline in eGFR of similar or greater magnitude has also been observed with renin-angiotensin-aldosterone system inhibitors and sodium glucose cotransporter inhibitors”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “Declines in eGFR paralleled the reduction in systolic AOBP and were consistent with expected lowering of intraglomerular pressures”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “Nine participants experienced an eGFR (cystatin C) decrease ≥25%. There were no eGFR decreases ≥50%”
> “Three participants discontinued treatment because of AEs, 2 attributed to lorundrostat treatment (hyperkalemia/acute kidney injury and CKD worsening) and 1 to placebo treatment (retinal detachment).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

> “During the lorundrostat treatment period, an anticipated, modest decrease in mean eGFR was observed (-6.8% lorundrostat, -4.6% mL/min/1.73m2 placebo-adjusted). Reduction in eGFR is also seen with other renin-angiotensin-aldosterone pathway inhibitors, including ACE inhibitors, ARBs, and MRAs.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

> “An early drop in eGFR was observed, as expected, after which eGFR remained stable within each study”

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-2.1.2.7.1-13"></a>

#### Symptomatic hypotension

> “Prespecified adverse events of special interest included 3 participants (2%) with hypotension.”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “Across all cohorts, dizziness (of mild intensity) was reported by nine (10.3%) lorundrostat‐treated participants compared with one (3.4%) placebo‐treated participant.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.7.1-14"></a>

#### Adrenal insufficiency and cortisol

> “The treatment-emergent adverse event of glucocorticoid insufficiency was reported in 0 participants in the 50 mg of lorundrostat group with possible escalation to 100 mg, in 3 participants (0.56%) in the 50 mg of lorundrostat group, and in 5 participants (1.9%) in the placebo group.”
> “There were no reports of hyperadrenocorticism.”
> “At week 12, the geometric mean for serum cortisol increased by 4.2% from baseline in the 50 mg of lorundrostat group with possible escalation to 100 mg, increased by 5.0% in the 50 mg of lorundrostat group, and decreased by 2.0% in the placebo group.”

Source: [Saxena et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12210145/)

> “No adrenocortical insufficiency occurred during the trial. Cosyntropin stimulation testing in participants randomized to 100 mg once daily in both cohort 1 and cohort 2 was normal, with stimulated values of cortisol greater than 18 µg/dL in all individuals receiving cosyntropin”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

> “No clinically meaningful changes in serum cortisol were observed in either treatment sequence.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.7.1-15"></a>

#### Adverse events in healthy participants: first-in-human study

> “Lorundrostat was well tolerated and no serious TEAEs occurred during the study.”
> “The overall incidence of TEAEs was comparable between participants treated with lorundrostat (41/87 [47%]) and those treated with placebo (18/29 [62%]).”
> “None of the subjects reached the stopping criterion for potassium of 6.0 mmol/L.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.7.1-16"></a>

#### Company risk factors: adverse effects and labeling

> “Use of lorundrostat or any future product candidates could be associated with adverse side effects, adverse events, or other properties or safety risks, which could delay or preclude regulatory approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label, or result in other significant negative consequences”
> “Undesirable side effects caused by our product candidates when used alone or in combination with approved or investigational drugs could cause us or regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label, or lead to the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities.”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="topic-2.1.2.7.1-17"></a>

#### Class context: warnings and precautions for the approved aldosterone synthase inhibitor baxdrostat

> “BAXFENDY can cause hyperkalemia”
> “Assess serum potassium prior to initiation of BAXFENDY and monitor periodically during treatment.”
> “More frequent monitoring is recommended for patients at increased risk of hyperkalemia (e.g., patients ≥ 65 years of age, those with diabetes mellitus or chronic kidney disease, and those receiving concomitant medications that increase serum potassium)”
> “Permanently discontinue BAXFENDY if clinically significant hyperkalemia recurs.”
> “BAXFENDY can cause hyponatremia”
> “Assess serum sodium prior to initiation of BAXFENDY and monitor periodically during treatment.”

Source: [AstraZeneca BAXFENDY prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219878Orig1s000lbl.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
